Ibrutinib is a first-generation oral BTK inhibitor that has been clinically approved by the United States Food and Drug Administration (FDA) for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (29). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.